Aurobindo Pharma’s consolidated net profit declined 12 per cent to ₹456 crore in the first quarter ended June 30, against ₹518.5 crore in the corresponding quarter of FY18.
The revenue of the Hyderabad-based company, however, grew 15.5 per cent to ₹4,250 crore, against ₹3,679 crore in the year-ago period.
“Growth in revenues was led by a healthy growth across key geographies and segments. However, profitability was impacted largely due to certain one-off product-related provisions,” N Govindarajan, Managing Director, Aurobindo Pharma, said in a release issued here on Thursday.
The company had started filing dermatology ANDAs and was on track in other specialty segments, he added.
Formulation sales in the US increased 11.5 per cent to ₹1,889.6 crore (₹1,695 crore) while in Europe they went up 30 per cent to ₹1,199 crore. The US accounted for 44.5 per cent of total revenues.
The company filed seven ANDAs, including three ANDAs for injectables, with the USFDA during the quarter. It received final approval for 13 ANDAs and tentative approval for three ANDAs from the US regulator.
The company’s scrip lost 1.72 per cent on the BSE on Thursday to end at ₹600.90.